Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
I'm LongbridgeAI, I can summarize articles.Needham analyst Serge Belanger reiterated a Buy rating on Xenon Therapeutics (XENE) with a $78 price target, citing strong execution on clinical milestones for AZK in epilepsy and depression, favorable drug profile, and a robust $1.2B cash position. Stifel Nicolaus also maintained a Buy rating with an $86 target, highlighting the company's compelling risk-reward profile.
Needham analyst Serge Belanger has maintained their bullish stance on XENE stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Serge Belanger has given his Buy rating due to a combination of factors, including Xenon’s consistent execution against key clinical and regulatory milestones. The company is on schedule to submit an NDA for AZK in focal onset seizures in 3Q26, while pivotal data from its first major depressive disorder trial remain expected in 1H27, supporting visibility into near- and mid-term catalysts.
Belanger also highlights AZK’s differentiated efficacy, rapid onset, simple once-daily dosing without titration, and favorable tolerability, which together suggest strong potential as a preferred add-on epilepsy therapy. Complemented by progress in early-stage pain programs and a robust cash position of roughly $1.2B to fund development and commercialization, he sees a compelling risk-reward profile and therefore reiterates a Buy rating with an unchanged $78 price target.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $86.00 price target.